We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer.
- Authors
Yuping Fu; Dandan Li; Ya Zhu; Sha Yan; Xia Wang; Zhenshuai Lian; Qi Xie; Zhi'an He
- Abstract
Background: This study aims to investigate the application value of serum cytokeratin 19 fragment (CYFRA21-1) combined with nerve-specific enolase (NSE), carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC-Ag) in the diagnosis of lung cancer (LC). Methods: A total of 831 cases of LC, 360 cases of benign lung disease (BLD) and 102 healthy controls, were enrolled. The data were processed using SPSS, GraphPad Prism, and MedCalc software. Results: The tumor marker (TM) levels in the LC and BLD groups were significantly higher than those in the control group; the CYFRA21-1, NSE, and CEA levels in the patients with LC were higher than in those with BLD. In particular, the increase was predominantly observed for the levels of CEA and CYFRA21-1 in adenocarcinoma (LUAD), CYFRA21-1 and SCC-Ag in squamous cell carcinoma (LUSC), and NSE in small cell carcinoma (SCLC). The CYFRA21-1, NSE, and CEA levels were significantly higher in stage IV than in other stages in LC. Univariate binary logistic analysis showed that increased levels of all four TMs were risk factors for BLD and LC. The area under the curve (AUC) of CYFRA21-1 was most effective in distinguishing patients with BLD or LC from the controls and in distinguishing patients with BLD and LC. The AUCs of combined CYFRA21-1, NSE, and CEA were increased to 0.755, 0.922, and 0.783, respectively, with no significant difference with the AUC of the four combined tests. In the histological classification, the best predictors were CEA, for LUAD, CYFRA21-1 for LUSC, and NSE for SCLC. Moreover, the expression levels of CYFRA21-1, NSE, and CEA significantly decreased after each treatment course. Conclusions: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.
- Subjects
LUNG cancer; SMALL cell carcinoma; SQUAMOUS cell carcinoma; CARCINOEMBRYONIC antigen; TUMOR markers; SERUM
- Publication
Clinical Laboratory, 2024, Vol 70, Issue 4, p641
- ISSN
1433-6510
- Publication type
Article
- DOI
10.7754/Clin.Lab.2023.230662